Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment

Details for Australian Patent Application No. 2006251429 (hide)

Owner Bayer Healthcare AG

Inventors Scheuring, Urban; Bernard, Ingo

Agent Davies Collison Cave

Pub. Number AU-A-2006251429

PCT Pub. Number WO2006/125540

Priority 05011477.6 27.05.05 EP

Filing date 13 May 2006

Wipo publication date 30 November 2006

International Classifications

A61K 31/4412 (2006.01) - having oxo groups directly attached to the heterocyclic ring

A61K 31/436 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

13 December 2007 PCT application entered the National Phase

  PCT publication WO2006/125540 Priority application(s): WO2006/125540

15 April 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006251434-Thermosetting powder compositions

2006251428-Combination therapy comprising diaryl ureas for treating diseases